Trial Profile
Phase II clinical dose-ranging trial with FP 1097 in women suffering from urinary incontinence or overactive bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2011
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Adverse reactions; Therapeutic Use
- Sponsors FemmePharma Global Healthcare
- 12 Jan 2011 New trial record
- 11 Jan 2011 Results reported in a FemmePharma media release.